GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (FRA:4LSA) » Definitions » Investments And Advances

Athersys (FRA:4LSA) Investments And Advances : €0.00 Mil (As of Sep. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Athersys Investments And Advances?

Athersys's Investments And Advances for the quarter that ended in Sep. 2023 was €0.00 Mil.


Athersys Investments And Advances Historical Data

The historical data trend for Athersys's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Investments And Advances Chart

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Athersys Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Athersys (FRA:4LSA) Business Description

Traded in Other Exchanges
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Athersys (FRA:4LSA) Headlines

No Headlines